Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Investment will fund expansion to meet rising demand for CRDMO services
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
In the near term, the company targets a 42% reduction in absolute Scope 1 and 2 emissions and Scope 3 emissions by FY2030
CPHI & PMEC India Expo 2024 to bring over 50,000 industry professionals and 2,000 exhibitors under one roof
Modernization and supply chain diversity drive new growth
Pharma CDMO business has posted a 40% YoY in Q2 driven by BD efforts and backed by macro tailwinds
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Subscribe To Our Newsletter & Stay Updated
